CN107823185B - Oral administration system taking composite nano material as carrier - Google Patents

Abstract

The invention discloses an oral administration drug delivery system taking composite nano materials as a carrier, which takes composite nano materials HP55 and PBCA as shells to coat a drug solution to form nano particles. The method adopts the composite nano material with biodegradability and good biocompatibility as the carrier of the oral drug, and can improve the bioavailability of the oral drug. In the field of biomedicine, the nano-particles can be used for orally presenting helicobacter pylori subunit vaccines and play a great role in preventing and treating diseases related to helicobacter pylori infection.

Description

Oral administration system taking composite nano material as carrier

Technical Field

The invention belongs to the field of new dosage forms of pharmaceutical preparations, and relates to an oral administration system taking a composite nano material as a carrier and application thereof, in particular to preparation of HP55/PBCA nano particles and application thereof in oral helicobacter pylori subunit vaccines.

Background

Oral vaccines (particularly novel vaccines such as DNA vaccines and recombinant protein polypeptide vaccines) are directly influenced by the pH environment and various enzyme systems in the gastrointestinal tract, so that active vaccines are degraded and inactivated, the absorption efficiency and the bioavailability are generally low, the antigen concentration at a target inoculation part is insufficient, and effective immune response reaction is generally difficult to initiate. Thus, special oral vaccine presentation systems are needed. At present, the particle presentation carrier in one of the active fields of vaccine presentation system research can protect antigen from being damaged by complex physiological environment, form antigen storage bank, facilitate the slow release of antigen, enhance the stability of therapeutic polypeptide and protein, and avoid the discharge of drug by intestinal cell through endocytosis and intestinal mucosa. And the particles with the particle size of less than 10 mu M can be absorbed by M cells in Peyer's knot of intestinal tract and enter systemic circulation through lymphatic circulation, thereby bypassing portal vein, avoiding first-pass metabolism of liver, further improving oral absorption of medicine, and further improving antigen immunogenicity and immune specificity. In addition, the particles are modified and optimized in a physical or biological mode (such as charge, particle size, hydrophobicity and surface ligand), the physicochemical properties of the particles are changed, and a targeting preparation is prepared, so that the vaccine can be targeted to an absorption part to improve the absorption efficiency and the immune efficiency, and the vaccine can play a better synergistic role in protecting the vaccine and promoting the absorption.

Helicobacter pylori (H.pylori: (Helicobacter pyloriHp) is a microaerophilic gram-negative bacillus which colonises mainly the gastric mucosa and which infects helicobacter pylori in an average of about 50% of the population worldwide. Chronic infection with Hp can cause chronic gastritis, peptic ulcers, atrophy of the gastric mucosa and metaplasia of the intestinal epithelium, and may even eventually lead to gastric cancer. Currently, the treatment of Hp infections is mainly based on "triple" therapy, i.e. antibiotic, proton pump inhibitor and bismuth agent combination therapy. However, the use of antibiotics to treat Hp infection has increased drug resistance, great side effects and failure to prevent repeated infection, so the development and application of Hp vaccines are expected to become the most effective way to control the prevalence of Hp infection. Experimental research shows that oral vaccination can cause effective specific immune response, prevent and even treat Hp infection, and enable organisms to obtain more lasting immunity.

Hydroxypropyl methylcellulose phthalate (HPMCP) is an enteric coating material, can prevent degradation of drugs in the stomach, is non-toxic, has good biocompatibility, and has been recorded in the United states pharmacopoeia, European pharmacopoeia and Japanese pharmacopoeia. Due to its excellent properties, it has been promoted to expand its range of use in other fields, including sustained release agents, formulations, binders and microcapsule ingredients. The pH critical value of HPMCP for rapid disintegration can be adjusted by changing the proportion of ester groups, so that the HPMCP has special pH sensitivity. HP-55, a specific HPMCP, is insoluble at pH values below 5.5, and is effective in resisting irritant gastric acid and reducing the loss of oral drugs in stomach. Acid-resistant HP55/PLGA nanoparticles have been investigated in the prior art for delivery of Helicobacter pylori vaccines, (TAN ZL, LIU W, LIU H, et al, Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles protein protection [ J ]. European Journal of pharmaceuticals and biopharmaceutical therapeutics, 2017,111: 33-43.) have demonstrated that HP55 is resistant to the acidic environment of the stomach, but since PLGA itself is polymerized by lactic acid and glycolic acid in ester linkages, hydrolysis against gastrointestinal proteases is weak and bioavailability of Oral protein drugs remains to be improved.

Disclosure of Invention

The invention aims to provide an oral administration system taking a composite nano material as a carrier, in particular to a compound HP55/PBCA nano particle, which can be used for presenting a vaccine orally, reducing the degradation of protease and gastric acid in gastrointestinal tracts to antigen protein and increasing the granularity of the vaccine so as to enhance the immunogenicity and the immune specificity of the vaccine. Specifically, taking a helicobacter pylori vaccine with double antigen epitopes and double adjuvants as an example, the invention provides an oral nanoparticle capable of effectively preventing and treating helicobacter pylori infection.

The specific technical scheme of the invention is as follows:

an oral administration system taking composite nano material as a carrier takes the composite nano material as a shell to coat a drug solution to form nano particles, wherein the composite nano material is HP55 and PBCA. The medicine is selected from one or more of helicobacter pylori vaccine, insulin and lysozyme. According to a specific scheme of the invention, the double-antigen epitope-double-adjuvant helicobacter pylori vaccine is used as a load drug of nanoparticles.

The mass-to-volume ratio of HP55 to PBCA in the above oral system is 1:2-2.5, preferably 1: 2.

The drug delivery system adopts an interfacial polymerization method to design compound HP55/PBCA nano-particles for encapsulating drugs, and the specific technical scheme is as follows:

the preparation method can be prepared by the following steps:

(1) weighing HP55 and a proper amount of BCA monomer according to a prescription, dissolving in an organic solvent, preferably acetone and/or ethanol, and preparing a drug-loaded organic phase;

(2) weighing appropriate amount of stabilizer, preferably poloxamer 188 and/or dextran-70, dissolving in the solution containing the medicine to obtain water phase solution;

(3) and (3) dropwise adding the organic phase obtained in the step (1) into the aqueous phase obtained in the step (2), continuing stirring after dropwise adding is finished, and evaporating to remove the organic phase to obtain the HP55/PBCA nanoparticle suspension. The resulting HP55/PBCA nanoparticle suspension may be further dried, for example by placing the HP55/PBCA nanoparticle suspension in a suitable container, pre-freezing at-20 ℃ for 12h, and freeze-drying for storage.

The invention is a specific technical scheme, the organic phase is acetone, BCA monomer (n-butylcyanoacetate) and HP55 (hydroxypropyl methyl cellulose phthalate) are dissolved in the acetone; the aqueous phase was an antigen protein solution containing 1% poloxamer 188. The vaccine is a dual-antigen epitope-dual-adjuvant helicobacter pylori vaccine.

Preferably, the BCA monomer of the step (1) has a volume percentage of 1% in the organic phase.

Preferably, the step (3) is magnetically stirred at the speed of 350rpm, and the particle size and the stability of the prepared nanoparticles are optimal.

The dual antigen epitope-dual adjuvant Helicobacter pylori vaccine CTB-UE-CF (CCF) can be prepared by the method disclosed in the literature SONG H, LV X, YANG J, et al, A novel pharmaceutical fluoride with the multi-epitope vaccine CTB-UE present Helicobacter pylori viral vaccine a BALB/c mouse model [ J ] Applied microbiology and biotechnology 2015, 99 (22): 9495-.

According to a specific technical scheme, the compound HP55/PBCA nano-particle (named as HP55/PBCA-CCF NPs) encapsulating the multi-epitope antigen protein CCF is designed:

(1) 25mg of HP55 and 50. mu.L of BCA monomer (1: 2 by mass/volume) were weighed out and dissolved in 5mL of acetone to obtain an organic phase.

(2) Antigenic protein CCF was dissolved in renaturation buffer (50 mmol/L NaH)₂PO₄10mmol/L Tris-HCl, 2mmol/L GSH, 0.4mmol/L GSSH, adjusting the pH value to 7.0 with HCl or NaOH, the concentration is about 3.0mg/mL, and the poloxamer 188 with the concentration of 1 percent is used as a non-ionic surfactant in the preparation process of the emulsion, so that the structural stability of the nano-particles is improved.

(3) And (3) dropwise adding the organic phase into the water phase by using an injector under the condition of magnetic stirring at 350rpm at 4 ℃, continuously stirring for 4.5 hours after the dropwise adding is finished, evaporating and removing the acetone, and finally filtering by using a 0.45-micrometer filter membrane to obtain the milky stable and uniform HP55/PBCA nanoparticle suspension.

(4) The nanoparticle suspension was pre-frozen in a suitable container at-20 ℃ for 12h, and stored freeze-dried.

It is another object of the present invention to provide the use of the delivery system of the present invention for improving the stability of a drug against proteases and gastric acid in the gastrointestinal tract. Can be used as a pharmaceutical preparation for presenting oral vaccines, reduces the degradation of protease and gastric acid in the gastrointestinal tract to antigen protein, and increases the granularity of the vaccine, thereby enhancing the immunogenicity and the immune specificity of the vaccine.

The invention also aims to provide the application of the oral vaccine delivery system taking the composite nano material as the carrier in preparing the medicines for preventing and treating the helicobacter pylori infection.

The invention has the advantages that:

(1) the drug delivery system has good biocompatibility and can be degraded and eliminated in organisms.

(2) The drug delivery system can reduce the strong acid environment in the stomach and the degradation and damage of gastrointestinal digestive enzymes to active substances, and improve the oral utilization rate. Poly (n-butyl cyanoacrylate, PBCA) is produced by polymerizing n-butyl cyanoacrylate monomer (BCA), and is a raw material of medical glue approved by the United states Food and Drug Administration (FDA). Has the advantages of low toxicity, sustained drug release, biodegradability, simple preparation method, targeting effect in vivo, high drug-loading rate and the like, and is widely applied to a sustained and controlled release drug delivery system. The invention applies the protein drug presentation system for oral administration, resists the digestion of protease in gastrointestinal tract and can obviously improve the bioavailability of the protein drug.

(3) According to the drug delivery system, antigen drugs can be slowly released in small intestines, the contact time with immune cells is prolonged, the immunogenicity of antigens is improved, the immune system can be directly activated, Th1/Th17 type cellular immune response is caused, local mucosal immunity is enhanced, the specific immune response of organisms to the antigens is promoted, meanwhile, the dosage of immune substances can be reduced, and the infection of helicobacter pylori can be effectively prevented and treated.

(4) The drug delivery system can provide a carrier for other oral drugs, and reduce the damage of the digestive tract environment to the drugs, thereby improving the concentration of the drugs absorbed by the small intestine into the blood.

(5) The preparation process of the drug delivery system is simple, and the prepared finished product is stable and convenient to store, so that the production cost of the vaccine is reduced. The oral vaccine is beneficial to entering clinical stage research, and the application field is bright in future.

The composite nano material is used as a carrier of an oral administration system, and the prepared composite nano particles can present oral vaccine medicaments, reduce the degradation of protease and gastric acid in gastrointestinal tracts to antigen protein and increase the granularity of the vaccine, thereby enhancing the immunogenicity and the immune specificity of the vaccine and achieving the effects of preventing and treating diseases.

Drawings

FIG. 1: particle size distributions of PBCA-CCF NPs and HP55/PBCA-CCF NPs.

FIG. 2: images of PBCA-CCF NPs and HP55/PBCA-CCF NPs were taken by transmission electron microscopy.

FIG. 3: PBCA-CCF NPs and HP55/PBCA-CCF NPs release efficiency curves in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF).

FIG. 4: time axis of mice immunization, challenge and sample collection.

FIG. 5: PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines induce detection of overall antibody levels.

FIG. 6: PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccine induce mucosal immune response level detection.

FIG. 7: pharmacodynamic evaluation of PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines.

FIG. 8: PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccine induced cytokine level detection.

Detailed Description

The following examples illustrate specific steps of the present invention, but are not intended to limit the invention.

Terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified.

The present invention is described in further detail below with reference to specific examples and with reference to the data. It will be understood that this example is intended to illustrate the invention and not to limit the scope of the invention in any way.

In the following examples, various procedures and methods not described in detail are conventional methods well known in the art.

The present invention is further illustrated by the following specific examples.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

Example 1: preparation of PBCA-CCF NPs and HP55/PBCA-CCF NPs.

(1) The prescribed amount of 25mg HP55 and BCA monomer, 50. mu.L imbibed, were weighed out and dissolved in 5mL acetone to make a drug-loaded organic phase for use.

(2) 50mg of poloxamer 188 is weighed and dissolved in 5mL of antigen protein solution obtained by separation and purification in the laboratory, and aqueous phase solution is prepared.

(3) And (3) dropwise adding the organic phase prepared in the step (1) into the water phase prepared in the step (2) by using an injector under the condition of 4 ℃ and in a magnetic stirring state of 350rpm, continuously stirring for 4.5 hours after dropwise adding is finished, evaporating and removing acetone, and finally filtering by using a 0.45-micrometer filter membrane to obtain the milky stable and uniform HP55/PBCA nano-particle suspension.

(4) The nanoparticle suspension was pre-frozen in a suitable container at-20 ℃ for 12h, and stored freeze-dried.

Using the same method and the same proportions as described above, PBCA-CCF NPs were prepared using BCA and CCF without addition of HP55 in step (1).

It was determined that the encapsulation efficiency of the HP55/PBCA nanoparticles encapsulating CCF prepared in this example was 55.04%, the particle size of the nanoparticles was 218.6 ± 4.7nm, the polydispersity was 0.158 ± 0.061, the encapsulation efficiency of the PBCA nanoparticles encapsulating CCF was 49.74%, the particle size of the nanoparticles was 168.4 ± 6.8nm, and the polydispersity was 0.202 ± 0.096.

In this example, fig. 1, 2 and 3 show the particle size distribution of PBCA-CCF NPs and HP55/PBCA-CCF NPs, images taken by transmission electron microscopy and release efficiency curves in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF), respectively, and the results show that the prepared composite nanoparticles have high spheronization rate, smooth, round, compact and well-formed surface, and the composite nanoparticles can reduce the degradation of protein vaccine in both Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF) and have a sustained release function, compared to PBCA-CCF NPs, although both have similar protective effects on vaccine proteins in Simulated Intestinal Fluid (SIF), HP55/PBCA-CCF NPs have stronger protein protective ability in Simulated Gastric Fluid (SGF), so that when proteins are orally administered, they pass through the environment vaccine in stomach, the HP55/PBCA-CCF NPs can resist the harsh environment of the stomach better than PBCA-CCF NPs, so that more CCF vaccine proteins are protected from entering the intestinal environment to stimulate the small intestinal mucosal immune system, and a stronger immune protection effect is achieved.

Example 2: PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines induce high levels of systemic immune responses.

(1) SPF-grade BALB/c mouse grouping protocol: (A) NC group: mice were orally administered with 500 μ L of a suspension of PBS and aluminum hydroxide adjuvant. (B) HP 55/PBCA-group: mice were orally administered complex HP55/PBCA nanoparticles without encapsulated antigen. (C) HP55/PBCA-CCF group: mice were orally administered complex HP55/PBCA nanoparticles encapsulating 100 μ g CCF. (D) PBCA-CCF group: mice were orally administered PBCA nanoparticles of the general type encapsulating 100 μ g CCF. (E) Alum-CCF group: mice were orally administered a suspension of 100 μ g CCF and aluminum hydroxide adjuvant.

(2) Mouse immunization and challenge protocol: according to fig. 4, the immunizations were performed orally 4 times with 7 days intervals, and two weeks later, the immunised mice were challenged once: hp suspension (1X 10) was administered by gavage⁹CFU/mL), 0.3 mL/mouse. Mice should be fasted 12h before each immunization and challenge.

(3) Serum sample collection protocol: according to fig. 4, serum samples were collected at the time points corresponding to the inverted triangle pattern: blood is taken from inner canthus of eye, and the mixture is placed at room temperature for 20min, frozen on ice for 2h, centrifuged at 4500 rpm for 15min, and the supernatant is carefully collected and stored at-80 ℃ after subpackage.

(4) ELISA detection of specific antibodies in antiserum:

ELISA reagents: (A) coating liquid: beijing Sorley technologies, Inc. (B) Washing liquid: weighing 0.2g KH₂PO₄，2.9g Na₂HPO₄•12H₂O, 8.0g NaCl, 0.2g KCl, 0.5mL Tween-20, add ddH₂O to 1000mL (PBST). (C) Sealing liquid: 3.0g of BSA was weighed and dissolved in 100mL of washing buffer, filtered and sterilized, and then stored at 4 ℃. (D) Sample diluent: 1.0g of BSA was weighed and dissolved in 100mL of washing buffer, followed by filtration sterilization and storage at 4 ℃. (E) Substrate solution: soluble mono-component TMB substrate solution. (F) Stopping liquid: 178.3mL of distilled water was measured out, and 21.7mL (1M H) of concentrated sulfuric acid was added dropwise₂SO₄)。

The detection scheme comprises the following steps: the native urease antigen was diluted to 10. mu.g/mL with coating solution, 100. mu.L was added per well and coated overnight at 4 ℃. Wash 4 times with PBST and pat dry. Add 300. mu.L of blocking solution to each well and block for 2h at 37 ℃. Wash 4 times with PBST and pat dry. Each group of antiserum and mouse negative serum was diluted in multiple ratios with a sample diluent, added to an ELISA plate at 100. mu.L/well, and incubated at 37 ℃ for 1 h. Wash 4 times with PBST and pat dry. HRP-labeled goat anti-mouse IgG (1: 2000) was added at 100. mu.L/well and incubated at 37 ℃ for 1 h. Wash 5 times with PBST and pat dry. Adding 100 mu L of TMB substrate developing solution, reacting for 15min at room temperature in a dark place, and adding 100 mu L of stop solution to stop the reaction. With enzymesMeasuring each hole OD by standard instrument₄₅₀The value is obtained.

As a result: as shown in fig. 5, HP55/PBCA-CCF NPs were administered orally to mice before and after challenge to induce higher levels of serum-specific IgG, IgA, and IgM, relative to PBCA-CCF NPs, which resulted in higher levels of systemic immunity and significantly enhanced vaccine immunogenicity.

Example 3: PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines induce the production of secretory IgA.

Helicobacter pylori can selectively colonize gastric mucosa, and if the helicobacter pylori cannot be cleared, chronic inflammation can be caused. Secretory IgA is a mark of local mucosal immune response, and detection of gastric sIgA has guiding significance for judging the prevention and treatment effects of vaccines.

Gastric mucosa sample collection protocol: according to FIG. 4, 4 weeks after the last immunization, the mice were sacrificed by intraperitoneal injection of excess ether, the stomach of the mice was taken, the stomach was longitudinally cut along the greater curvature of the stomach, 0.1g of the stomach tissue was taken, 500. mu.L of PBS was added, homogenization was performed sufficiently with a homogenizer, centrifugation was performed at 3000rpm for 30min, and the supernatant was collected.

To study the level of gastric mucosal immunoreactivity, we used ELISA to detect sIgA levels in the stomach.

ELISA reagents: (A) coating liquid: beijing Sorley technologies, Inc. (B) Washing liquid: weighing 0.2g KH₂PO₄，2.9g Na₂HPO₄•12H₂O, 8.0g NaCl, 0.2g KCl, 0.5mL Tween-20, add ddH₂O to 1000mL (PBST). (C) Sealing liquid: 3.0g of BSA was weighed and dissolved in 100mL of washing buffer, filtered and sterilized, and then stored at 4 ℃. (D) Sample diluent: 1.0g of BSA was weighed and dissolved in 100mL of washing buffer, followed by filtration sterilization and storage at 4 ℃. (E) Substrate solution: soluble mono-component TMB substrate solution. (F) Stopping liquid: 178.3mL of distilled water was measured out, and 21.7mL (1M H) of concentrated sulfuric acid was added dropwise₂SO₄)。

The detection scheme comprises the following steps: the native urease antigen was diluted to 10. mu.g/mL with coating solution, 100. mu.L was added per well and coated overnight at 4 ℃. Wash 4 times with PBST and pat dry. Add 300. mu.L of blocking solution to each well and block for 2h at 37 ℃. Wash 4 times with PBST and pat dry. Stomach of each group of miceThe supernatant was diluted two-fold with sample diluent and added to ELISA plates at 100. mu.L/well and incubated for 1h at 37 ℃. Wash 4 times with PBST and pat dry. HRP-labeled goat anti-mouse IgA (1: 2000) was added at 100. mu.L/well and incubated at 37 ℃ for 1 h. Wash 5 times with PBST and pat dry. Adding 100 mu L of TMB substrate developing solution, reacting for 15min at room temperature in a dark place, and adding 100 mu L of stop solution to stop the reaction. Determination of OD in each well by enzyme-linked immunosorbent assay₄₅₀The value is obtained.

As a result: as shown in FIG. 6, significantly elevated sIgA was detected in the stomach of mice orally administered with HP55/PBCA-CCF NPs relative to PBCA-CCF NPs, indicating that the HP55/PBCA-CCF NPs vaccine induces a stronger local mucosal immune response, which is beneficial for effective elimination of helicobacter pylori infection.

Example 4: pharmacodynamic studies of PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines.

Gastric mucosa sample collection protocol: according to FIG. 4, 4 weeks after the last immunization, the mice were sacrificed by intraperitoneal injection of excess ether, the stomach of the mice was taken, the stomach was longitudinally cut along the greater curvature of the stomach, 0.1g of the stomach tissue was taken, 500. mu.L of PBS was added, and the mixture was thoroughly homogenized with a homogenizer.

Culturing the fixed planting amount of helicobacter pylori in stomach tissue:

homogenizing stomach tissue according to the proportion of 1: 10,1: 100 and 1: after 1000 dilution, 10. mu.L of the suspension was applied to a selective medium for helicobacter pylori. Cultured at 37 ℃ for 3 days under microaerophilic conditions. The number of colonies contained per mg of stomach tissue (CFU/mg) was calculated by counting the characteristic colony morphology of helicobacter pylori.

As a result: as shown in figure 7, compared with PBCA-CCF NPs, the HP55/PBCA-CCF NPs oral vaccine can obviously reduce the colonization of helicobacter pylori in the stomach and enhance the immunoprotection of mice.

Example 5: oral immunization of PBCA-CCF NPs and HP55/PBCA-CCF NPs vaccines induced cytokine production.

(1) The mouse spleen lymphocyte culture method comprises the following steps:

the mouse lymphocytes are extracted by using lymphocyte separating medium, and 100 mu L (5 multiplied by 10) of mouse lymphocyte suspension of each group is added into a 24-hole flat-bottom cell culture plate⁵One/hole) Simultaneously, antigen stimulators (natural urease antigen, concentration of which is 20 mug/mL) are respectively added. Culture medium was supplemented to a final volume of 500. mu.L/well, and 4 parallel wells per group were made. At 37 ℃ 5% CO₂Culturing for 72 h under the condition, and centrifuging to collect culture supernatant.

(2) Detecting mouse spleen lymphokine by using an ELISA kit:

the kit was removed from the 4 ℃ freezer and allowed to equilibrate at room temperature for 30 min. A standard sample hole and a sample hole are arranged, cytokine (IFN-gamma, IL-17) standard substances with different concentrations are added into the standard sample hole, and 100 mu L of a sample diluted by a sample diluent is added into the sample hole. Incubate at 37 ℃ for 90 min. Discarding the liquid and drying. Prepared biotin anti-mouse IFN-gamma and IL-17 antibody working solution is added according to 100 mu L per well. Incubate at 37 ℃ for 60 min. Washing for 4 times, and spin-drying. 100 μ L/well of ABC (avidin-peroxidase complex) working solution was added. Incubate at 37 ℃ for 30 min. Washing for 5 times, and spin-drying. Adding TMB developing solution 90 mu L/hole. The reaction was carried out at 37 ℃ for 20min with exclusion of light. TMB stop solution was added to each well at 100. mu.L. Measuring the OD value of each hole at the wavelength of 450 nm; and calculating a linear regression equation of the standard curve according to the concentration of the standard substance and the corresponding OD value, and calculating the corresponding sample concentration on the regression equation according to the OD value of the sample.

As a result: as shown in FIG. 8, oral administration of HP55/PBCA-CCF NPs vaccine stimulated the organism to produce higher levels of IFN-. gamma.and IL-17 relative to PBCA-CCF NPs. Indicating that it can cause stronger Th1/Th17 immune biased cell response which is crucial to the elimination of helicobacter pylori.

Claims (5)

1. An oral administration system taking a composite nano material as a carrier is characterized in that the composite nano material is taken as a shell to coat a drug solution to form nano particles, the composite nano material is hydroxypropyl methyl cellulose phthalate HPMCP and poly n-butyl cyanoacrylate PBCA, the HPMCP is HP55, and the mass-to-volume ratio of HP55 to PBCA is 1:2-2.5, and the oral administration system is prepared by the following steps:

(1) weighing HP55 and a BCA monomer absorbing n-butyl cyanoacrylate in a prescription amount, and dissolving the HP55 and the BCA monomer in an organic solvent, wherein the organic solvent is acetone and/or ethanol to prepare an organic phase;

(2) dissolving a proper amount of stabilizer in the solution containing the medicine, wherein the stabilizer is poloxamer and/or glucan-70, and preparing into an aqueous phase solution;

(3) dropwise adding the organic phase prepared in the step (1) into the aqueous phase prepared in the step (2), and continuously stirring after dropwise adding is finished

And (3) stirring, and evaporating to remove an organic phase to obtain an HP55/PBCA nanoparticle suspension, or further drying the obtained HP55/PBCA nanoparticle suspension.

2. Drug delivery system according to claim 1, characterized in that the drug is selected from one or several of the group consisting of helicobacter pylori vaccine, insulin, lysozyme.

3. Drug delivery system according to claim 2, characterized in that the drug is a dual antigen epitope-dual adjuvant helicobacter pylori vaccine.

4. The delivery system of claim 1, wherein the BCA monomer of step (1) is present in the organic phase at a concentration of 1% by volume.

5. Drug delivery system according to claim 1, characterized in that the mass to volume ratio of HP55 to BCA monomer is 1:2 to 2.5.

Images